You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials Completed
343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to October 2024

AbstractFullPdf
Nov 2021270012
Dec 20216608
Jan 20228404
Feb 20224303
Mar 202221803
Apr 202284013
May 202286024
Jun 202244011
Jul 20227801
Aug 202258010
Sep 20225607
Oct 20222809
Nov 20224009
Dec 20223004
Jan 20233003
Feb 20234204
Mar 20233808
Apr 202346018
May 20231801
Jun 20231002
Jul 20232208
Aug 20232601
Sep 20231601
Oct 20231603
Nov 20232002
Dec 20232603
Jan 20245402
Feb 20243608
Mar 20243802
Apr 20243003
May 20242001
Jun 20241005
Jul 20242603
Aug 20242605
Sep 20242203
Oct 20241607
Total17730211